Abstract：【Objective】 To investigate the effect of bevacizumab combined with conventional treatment on the levels of serum insulin growth factor-1 (IGF-1) and glial fibrillary acidic protein (GFAP) in patients with distant recurrence of glioma. 【Methods】A total of 78 patients with distant recurrence of glioma admitted to our hospital from January 2020 to January 2024 were selected and divided into the control group (treated with conventional therapy) and the observation group (treated with bevacizumab combined with conventional therapy) by the random number table method, with 39 cases in each group. The short-term therapeutic effects and long-term survival rates of the two groups of patients were compared. The levels of serum IGF-1 and GFAP before and after treatment, as well as the scores of the Stroke Scale (NIHSS) and the Quality of Life Scale for Cancer Patients (EORTIC QLQ-C30) of the two groups of patients were also compared. 【Results】The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the expression levels of serum IGF-1 and GFAP in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). After 1 month and 3 months of treatment, the NIHSS scores of both groups were lower than those before treatment, and the scores of the observation group were lower than those of the control group. The difference was statistically significant (P<0.05). The EORTIC QLQ-C30 scores of the two groups of patients were higher than those before treatment, and the observation group was higher than the control group. The difference was statistically significant (P<0.05). The 2-year and 3-year survival rates of patients in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Bevacizumab combined with conventional treatment can significantly improve the long-term survival rate of patients with distant recurrence of glioma, with good clinical efficacy. It can improve the neurological function of patients and enhance their quality of life.
袁兴, 王乃冰. 贝伐珠单抗联合常规治疗对胶质瘤复发患者血清IGF-1、GFAP水平的影响[J]. 医学临床研究, 2025, 42(5): 751-753.
YUAN Xing, WANG Naibing. The Influence of Bevacizumab Combined with Conventional Treatment on the Levels of Serum IGF-1 and GFAP in Patients with Distant Recurrence of Glioma. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 751-753.
2025, Vol. 42 
